Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefditoren pivoxil - Meiji Seika Pharma

Drug Profile

Cefditoren pivoxil - Meiji Seika Pharma

Alternative Names: CDTR-PI; CRTX-062; CRTX-068; ME-1207; Meiact; Meiact MS Fine Granules 10% - Meiji Seika Pharma; Spectracef

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Cornerstone Therapeutics; Meiji Seika Pharma; Tedec Meiji
  • Class Anti-infectives; Antibacterials; Cephems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Skin and soft tissue infections; Tonsillitis
  • Suspended Pharyngitis
  • No development reported Urinary tract infections

Most Recent Events

  • 01 Aug 2019 Launched for Bacterial infections (In children) in Indonesia (PO)
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 31 Mar 2011 Phase-III clinical trials in Bacterial infections (in children) in Japan (PO, Granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top